The research agreement $AIKI entered with University of Maryland, Baltimore should not be overlooked. On 5/4, that team became the first in the United States to begin testing four variations of a COVID-19 vaccine candidate. It uses mRNA, just like Moderna. UMB’s team is working with large companies like Pfizer and has a good shot of being one of four or so vaccines that are used in early 2021. Aiki Pharma, sponsoring this research, will benefit financially.
  • 3